London, 29 September 2014 – TechNavio, a global tech-focused research firm has announced the publication of its market research report on the Global H1N1 Vaccines Market 2014-2018.
H1N1 is an RNA virus and a type of influenza, which belongs to Orthomyxoviridae family and targets the nose, throat and lungs of the host.
The Global H1N1 Vaccines Market is growing at a moderate rate and is expected to post a CAGR of 5.40 percent during the forecast period.
The latest report by TechNavio focuses on the growing awareness about the disease, which is expected to increase the targeted population for vaccination. The report also emphasizes influenza vaccines that are available as trivalent and quadrivalent vaccines for active immunization, against three and four strains of influenza virus, respectively.
“Annually, the WHO analyzes and recommends influenza virus strains to be incorporated into flu vaccines for the upcoming flu seasons. Since 2012, the WHO started recommending an additional strain B to be used in quadrivalent vaccines along with the recommended strains for trivalent vaccines. In addition, Fluenz Tetra is intended to replace Fluenz in the EU for the 2014-2015 flu season,” says Faisal Ghaus, Vice President of TechNavio.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2018
Market Growth Drivers:
- Increase in Awareness
- For a full detailed list, view our report.
Market Challenges:
- Antigenic Drift of H1N1 Virus
- For a full detailed list, view our report.
Market Trends:
- Emergence of Quadrivalent Vaccines
- For a full detailed list, view our report.
Key Vendors:
- AstraZeneca plc
- GlaxoSmithKline plc
- Novartis AG
- Sanofi Pasteur SA
Other Prominent Vendors:
- Baxter International
- bioCSL
- Mitsubishi Tanabe Pharma
- Protein Sciences
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
